Summit Trail Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Summit Trail Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14	Closed	–	–	1991
2017 Q4	$0	Buy	+14	New	+$446	﹤0.01%	2156

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Summit Trail Advisors's GHDX Position: Q1 2018 in Review

Summit Trail Advisors sold out of Genomic Health, Inc. (GHDX) in Q1 2018, closing a stake of 14 shares.

Summit Trail Advisors first reported a position in GHDX in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 134 funds tracked by Wall St. Rank hold GHDX as of Q1 2018.

Summit Trail Advisors reported no remaining Genomic Health, Inc. position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 14 Genomic Health, Inc. shares in Q1 2018.
Summit Trail Advisors first reported a position in Genomic Health, Inc. in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Genomic Health, Inc. position peaked at $0 in Q4 2017.
134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.